Stock ADAP ADAPTIMMUNE THERAPEUTICS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Insiders Adaptimmune Therapeutics plc

Equities

ADAP

US00653A1079

Real-time Estimate Cboe BZX
Other stock markets
 03:05:52 2024-04-29 pm EDT 		5-day change 1st Jan Change
1.155 USD +7.44% Intraday chart for Adaptimmune Therapeutics plc +15.35% +46.91%
05:27pm European Equities Traded in the US as American Depositary Receipts Nudge Higher in Monday Trading MT
Apr. 24 European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT

Insiders

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Adaptimmune Therapeutics plc Appoints Cintia Piccina as Chief Commercial Officer, Effective March 18, 2024
CI
Adaptimmune Therapeutics plc Announces Resignation of Dr. Elliott Sigal as Member of the Board of Directors
CI
Adaptimmune Therapeutics plc Announces Management Changes
CI
Adaptimmune Therapeutics plc Appoints Joanna Brewer as Chief Scientific Officer
CI
Adaptimmune Therapeutics plc Appoints Cintia Piccina as Chief Commercial Officer, Effective January 31, 2022
CI
Adaptimmune Therapeutics plc Promotes Elliot Norry, Chief Medical Officer, to Executive Team Effective from January 1, 2021
CI
Adaptimmune Therapeutics plc Announces Retirement of Giles Kerr from the Board
CI
Adaptimmune Therapeutics plc Announces Board Changes
CI
Adaptimmune Therapeutics plc Announces Management Changes
CI
Adaptimmune Therapeutics plc Announces Appointment of Michael Garone as Interim Chief Financial Officer
CI
Adaptimmune Therapeutics plc Announces Management Changes
CI
Adaptimmune Therapeutics plc Announces Executive Changes
CI
Gwen Binder to Leave as Chief Technology Officer of Adaptimmune Therapeutics Plc, Effective January 31, 2019
CI
Rafael Amado Assumes New Role as President of Research and Development of Adaptimmune Therapeutics plc
CI
Adaptimmune Therapeutics plc Announces Board and Committee Changes
CI
Adaptimmune Therapeutics plc Announces Changes to Board of Directors, Effective from July 5, 2018
CI
Paul Stead Joins Adaptimmune Therapeutics as Vice President of Business Development
CI
Sébastien Desprez Joins Adaptimmune as Vice President of Communications and Investor Relations
CI
Adaptimmune Therapeutics plc Announces Management Appointments
CI
Adaptimmune Therapeutics plc Appoints Mark E. Dudley as Senior Vice President of Global Bio-Process and Development
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ADAP Stock
  4. News Adaptimmune Therapeutics plc
  5. Insiders